Optime Care Announces Enhanced Partnership with Rigel Pharmaceuticals for GAVRETO® Patients

Aug 6, 2024

ST. LOUIS--(BUSINESS WIRE)--Optime Care, a nationally recognized specialty pharmacy and an AscellaHealth Company, today announces a contractual partnership with Rigel Pharmaceuticals, Inc., effective July 1, 2024, bringing its comprehensive suite of services to support patients using GAVRETO® (pralsetinib). GAVRETO® is a targeted therapy that is taken by mouth once daily and is used to treat certain cancers caused by abnormal RET genes.

To read more, click here

Read our Privacy Policy to learn more. We use cookies to help us better understand how our customers interact with our website. Read our Privacy Policy to learn more.